Analyst Price Targets — HAE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 9, 2026 1:52 pm | Anthony Petrone | Mizuho Securities | $140.00 | $119.38 | TheFly | Haemonetics price target raised to $140 from $95 at Mizuho |
| October 9, 2026 11:34 am | — | Barrington | $140.00 | $119.47 | TheFly | Haemonetics price target raised to $140 from $118 at Barrington |
| October 8, 2026 1:19 pm | — | BTIG | $130.00 | $115.26 | TheFly | Haemonetics price target raised to $130 from $110 at BTIG |
| September 3, 2026 12:41 pm | Andrew Cooper | Raymond James | $125.00 | $102.96 | TheFly | Haemonetics price target raised to $125 from $105 at Raymond James |
| August 21, 2026 11:16 am | — | Robert W. Baird | $119.00 | $108.22 | TheFly | Haemonetics price target raised to $119 from $96 at Baird |
| August 19, 2026 11:33 am | — | Barrington | $118.00 | $104.65 | TheFly | Haemonetics price target raised to $118 from $95 at Barrington |
| August 7, 2026 1:39 pm | — | Raymond James | $105.00 | $85.73 | TheFly | Haemonetics price target raised to $105 from $90 at Raymond James |
| August 7, 2026 11:52 am | — | Robert W. Baird | $96.00 | $85.02 | TheFly | Haemonetics price target raised to $96 from $88 at Baird |
| August 7, 2026 11:42 am | — | Barrington | $95.00 | $85.02 | TheFly | Haemonetics price target raised to $95 from $89 at Barrington |
| August 6, 2026 5:21 pm | Marie Thibault | BTIG | $96.00 | $84.94 | StreetInsider | Haemonetics (HAE) PT Raised to $96 at BTIG |
Latest News for HAE
Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
On October 08, 2026, Haemonetics Corp (HAE) shares experienced a significant rise of 17.5%, bringing the current price to $119.47. The stock has seen remarkable
ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results of RAPIDe-3, a phase 3, global,…
Haemonetics (NYSE:HAE) shares jumped over 13% to $115.20 on Thursday after CSL set out a timetable for moving its US plasma collection centers onto the company's devices. CSL Limited (ASX:CSL), the Australian biotechnology company, expects to finish rolling out Haemonetics' NexSys PCS devices with Persona PLUS technology and related disposables by the end of 2027.
CSL Plasma plans to use Haemonetics' plasma collection equipment across all existing U.S. centers, expanding the scope of an earlier supply agreement.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HAE.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.